ISS ESG has upgraded the non-financial rating of Medincell from C+ to B, according to a press release from the French biotech published on Tuesday, February 10. The company is now ranked in the top decile of the Pharmaceutical & Biotechnologies sector and has achieved ISS ESG Prime status.
The rating agency ISS ESG has raised Medincell's overall rating following an independent evaluation covering multiple areas. According to the press release, this rating considers social factors and product responsibility, governance and business ethics requirements, as well as certain environmental indicators monitored by the company. ISS ESG also noted that Medincell benefits from a very high level of transparency in terms of non-financial information. The evaluation was based on publicly accessible information and exchanges with Medincell.
Impact on Company Visibility and Comparability
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Christophe Douat, CEO of Medincell, stated that the improvement in the ISS ESG rating could help enhance the visibility and comparability of the company's non-financial performance. According to him, this rating allows stakeholders to better appreciate how Medincell's practices align with their own risk management and sustainability criteria. Medincell indicates that ESG evaluations are increasingly integrated into the investment frameworks of institutional investors.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
